Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ActiRhino Immunité
- Development stage
- Unknown
- Lead developer
- Laboratoires Grimberg
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
ActiRhino Immunité (also known as ActiRhino Immunité Défenses Naturelles) is an over-the-counter dietary supplement developed by Laboratoires Grimberg to support the immune system and protect the upper respiratory tract (ENT/ORL sphere). It is formulated as strawberry-flavored lozenges (comprimés à sucer) containing a combination of the patented oral probiotic strain *Streptococcus salivarius* K12 (Bactoblis) and Vitamin D3 (cholecalciferol). *Streptococcus salivarius* K12 is a commensal bacterium that colonizes the oral cavity and nasopharynx, producing bacteriocins (salivaricins A2 and B) that inhibit common pathogens like *Streptococcus pyogenes*, thereby helping to prevent recurrent throat and ear infections. Vitamin D3 acts as an agonist of the Vitamin D receptor (VDR), contributing to the normal functioning of the immune system. The product is approved and marketed in France for adults and children from 3 years of age.
- Brand names
- ActiRhino ImmunitéActiRhino Immunité Défenses Naturelles
- Other names
- Streptococcus salivarius K12 + cholecalciferolStreptococcus salivarius K12 + vitamin D3
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on ActiRhino Immunité.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ActiRhino Immunité.